加载中
NASDAQHealthcareBiotechnology
最新数据
US$22.23
−US$1.14 · -4.88%
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
前收盘价
US$22.23
−US$1.14 · -4.88%
盘后
US$22.23
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
日内区间
当前US$22.23
52周区间
当前US$22.23
盘中时间采用ET。市场数据可能有所延迟。
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
日内区间
当前US$22.23
52周区间
当前US$22.23
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1.32亿 USD | 1.69亿 USD | 7036.1万 USD | 2625万 USD | 1630.8万 USD |
| 销售、一般及管理费用 | 3859.5万 USD | 2382.2万 USD | 1429.6万 USD | 522.9万 USD | 241.7万 USD |
| 营业费用 | 1.71亿 USD | 1.92亿 USD | 8465.7万 USD | 3147.9万 USD | 1872.5万 USD |
| 利息收入 | 1595.3万 USD | 1458.8万 USD | 1275.6万 USD | 167.6万 USD | — |
| 利息支出 | — | — | — | 167.6万 USD | 2.7万 USD |
| 折旧和摊销 | 5.9万 USD | 4.3万 USD | — | — | — |
| 营业利润 | −1.71亿 USD | −1.92亿 USD | −8465.7万 USD | −3147.9万 USD | −1872.5万 USD |
| 净利润 | −1.55亿 USD | −1.78亿 USD | −7189.8万 USD | −2979.9万 USD | −1940.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5052.17万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM3734.26万0.05%787.4亿 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI3379.3万0.34%103.03亿 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF1889.43万0.02%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1322.62万0.10%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB1100.37万0.10%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO847.07万0.05%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA821.9万0.04%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
